Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Prime Medicine (PRME)

Prime Medicine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PRME
DateTimeSourceHeadlineSymbolCompany
30/05/202413:00GlobeNewswire Inc.Prime Medicine to Present at Upcoming Investor ConferencesNASDAQ:PRMEPrime Medicine Inc
21/05/202421:06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PRMEPrime Medicine Inc
21/05/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
13/05/202413:00GlobeNewswire Inc.Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:PRMEPrime Medicine Inc
10/05/202413:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRMEPrime Medicine Inc
10/05/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
10/05/202413:00GlobeNewswire Inc.Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
08/05/202413:00GlobeNewswire Inc.Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
01/05/202413:00GlobeNewswire Inc.Prime Medicine to Participate in the 27th Annual Milken Institute Global ConferenceNASDAQ:PRMEPrime Medicine Inc
29/04/202412:00GlobeNewswire Inc.Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
23/04/202413:00GlobeNewswire Inc.Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific MeetingsNASDAQ:PRMEPrime Medicine Inc
01/03/202413:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRMEPrime Medicine Inc
01/03/202413:04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRMEPrime Medicine Inc
01/03/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
01/03/202413:00GlobeNewswire Inc.Prime Medicine Reports Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
28/02/202413:00GlobeNewswire Inc.Prime Medicine to Participate in Upcoming Investor ConferencesNASDAQ:PRMEPrime Medicine Inc
23/02/202422:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
23/02/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
23/02/202402:31Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:PRMEPrime Medicine Inc
20/02/202422:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
20/02/202421:01GlobeNewswire Inc.Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:PRMEPrime Medicine Inc
16/02/202411:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
16/02/202411:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRMEPrime Medicine Inc
15/02/202404:50GlobeNewswire Inc.Prime Medicine Announces Pricing of Upsized Public OfferingNASDAQ:PRMEPrime Medicine Inc
15/02/202402:57Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PRMEPrime Medicine Inc
14/02/202422:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRMEPrime Medicine Inc
14/02/202421:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
14/02/202421:05GlobeNewswire Inc.Prime Medicine Announces Proposed Public Offering of Common StockNASDAQ:PRMEPrime Medicine Inc
25/01/202413:00GlobeNewswire Inc.Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic FibrosisNASDAQ:PRMEPrime Medicine Inc
08/01/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:PRME

Your Recent History

Delayed Upgrade Clock